Volume | 10,066 |
|
|||||
News | - | ||||||
Day High | 127.7462 | Low High |
|||||
Day Low | 125.62 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sarepta Therapeutics Inc New | SRPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
127.53 | 125.62 | 127.7462 | 127.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
197 | 10,066 | $ 126.90 | $ 1,277,336 | - | 55.25 - 159.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:39:12 | 100 | $ 127.16 | USD |
Sarepta Therapeutics (SRPT) Options Flow Summary
Sarepta Therapeutics Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.96B | 93.86M | - | 1.24B | -535.98M | -5.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sarepta Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 116.55 | 130.61 | 114.37 | 122.22 | 1,058,720 | 10.61 | 9.10% |
1 Month | 129.38 | 130.61 | 114.37 | 123.08 | 721,466 | -2.22 | -1.72% |
3 Months | 122.00 | 143.00 | 114.37 | 126.44 | 834,203 | 5.16 | 4.23% |
6 Months | 107.39 | 143.00 | 55.25 | 100.36 | 1,338,135 | 19.77 | 18.41% |
1 Year | 122.55 | 159.89 | 55.25 | 110.33 | 1,254,272 | 4.61 | 3.76% |
3 Years | 71.37 | 159.89 | 55.25 | 102.31 | 1,109,617 | 55.79 | 78.17% |
5 Years | 120.02 | 181.83 | 55.25 | 107.55 | 1,131,617 | 7.14 | 5.95% |
Sarepta Therapeutics Description
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. |